CORRIGENDUM: Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease

The authors apologize for several inaccuracies identified in the section regarding supplementary information and funding of the manuscript. Corrections are shown below.

1) Supplementary File

The changes are Supplementary Figures 1–3 and Supplementary Tables 1–2.

Please find updated supplementary file(s);

https://doi.org/10.1253/circj.CJ-66-0244

2) Page 477, “Funding” and “Conflicts of Interest” section

Incorrect:

Funding

Following studies in Europe, North America and China, this study was initiated and funded by AstraZeneca Japan. All authors received funding from AstraZeneca Japan for the study. AstraZeneca Japan commissioned Triducive Partners Limited to facilitate the project and analyze the results in line with the Delphi methodology. After engaging Triducive Partners Limited, AstraZeneca made no contribution to the study design and development, outside of honoraria payments. AstraZeneca took no part in the writing, revision or editing of the manuscript, except checking no specific medicines were promoted and that all recommendations were appropriate to drug label.

Conflicts of Interest

All authors received honoraria from AstraZeneca while undertaking this study. K. Kuwahara, K.T. and K. Kinugawa are members of Circulation Journal’s Editorial Team. Detailed COIs are available at the end of the Supplementary Information.

Corrected:

Funding

Following studies in Europe, North America and China, this study was initiated and funded by AstraZeneca Japan. AstraZeneca Japan commissioned Triducive Partners Limited to facilitate the project and analyze the results in line with the Delphi methodology.

Conflicts of Interest

All authors received personal fee from AstraZeneca during conduct of this study. K. Kuwahara, K.T. and K. Kinugawa are members of Circulation Journal’s Editorial Team. Detailed COIs are available at the end of the Supplementary Information. AstraZeneca made no contribution to the Delphi study design and development, and took no part in the writing, revision or editing of the manuscript except checking that the manuscript contained no promotion of specific medicines and that all recommendations were appropriate to drug label.